Common questions about Varilrix (FAQ)
Q: Can Varilrix be given at the same time as other childhood shots?
Official studies support that Varilrix may be given at the same time as certain other routine vaccines, such as the measles-mumps-rubella vaccine (MMR). According to the official product information, if two or more vaccines are administered concurrently, each must be given as a separate injection at a different site.
Q: What happens if someone misses their scheduled dose of Varilrix?
Regulatory documents advise that if the first dose is missed, a healthcare professional typically addresses the appropriate catch-up schedule. For a missed second dose, official guidance indicates that it is generally given as soon as feasible to complete the full vaccination course.
Q: Can Varilrix cause a positive result on any laboratory tests?
Official documentation notes that the vaccine may cause a temporary reduction in the sensitivity of the Tuberculin Skin Test (TST), a test for tuberculosis exposure. This could potentially make the TST result unreliable, based on official information, if the test is performed within six weeks of vaccination. No other general lab test interference is commonly noted in the official materials.
Q: What does the medical literature say about Varilrix use in people with weakened immune systems?
The vaccine is generally contraindicated (must not be used) in individuals with severe immune deficiencies. However, official guidelines note that it may be considered for patients with selected immune deficiencies, such as asymptomatic HIV, only when a medical assessment must determine if the benefits outweigh the risks based on specific clinical criteria.
Q: What should be done if the injection site is red or swollen after the dose?
Redness and swelling at the injection site are officially documented as very common side effects following the dose. These are typical local reactions. Official documentation advises that any adverse events may be reported. If guidance is needed for managing these common reactions, or if symptoms worsen significantly, a healthcare professional can provide non-directive information.
Q: What is the general understanding of how long protection lasts after the full course of Varilrix?
Studies have shown that protective efficacy lasts for at least nine years following the full vaccination course. Official documents note that the need for a booster dose beyond the primary two-dose schedule has not yet been formally determined.
Q: Is Varilrix the same as other vaccines for the same disease?
Official documents classify Varilrix as a single-agent live attenuated vaccine that uses the Oka strain of the virus. While regulatory research has examined and compared its performance with other varicella vaccines, its specific formulation and components are different from other products.
Q: Why is Varilrix sometimes recommended for adults?
The vaccine is recommended for non-immune adolescents and adults because the chickenpox disease tends to be more severe and carries a higher risk for complications in older age groups. Official guidelines indicate the vaccine is intended for use in non-immune adults to address the risks associated with the disease in older age groups.
Q: How long after getting Varilrix is a person considered protected?
The earliest time point at which vaccine efficacy has been formally assessed in clinical trials is six weeks following the first dose in children or six weeks following the second dose in older individuals. This time window is when established protection is typically measured.
Q: What if a person has already been exposed to the illness; can they still receive Varilrix?
Official information indicates that the vaccine may be given to susceptible individuals for post-exposure use. For example, regulatory documents suggest that vaccination administered within three days of exposure may prevent or modify the course of the disease.
Q: Is there any research about Varilrix's long-term effectiveness?
Research data is available on protective efficacy for up to nine years following vaccination. Official documents, however, indicate that the need for subsequent booster doses has not yet been determined in the available regulatory research.
Q: What is Varilrix made of?
The vaccine contains the active ingredient, which is the Varicella-zoster virus (live attenuated Oka strain). It also contains stabilizers and excipients such as lactose anhydrous, sorbitol, mannitol, and amino acids (which contain phenylalanine).
Q: Does Varilrix contain any ingredients that might cause a severe reaction?
The vaccine is formally contraindicated (must not be used) in individuals with known hypersensitivity or allergy to the active substance, neomycin, or any of the other excipients contained in the vaccine. Screening for these allergies is described in official documents as a part of the eligibility review process.
Q: If a patient is allergic to eggs, can they still get Varilrix?
Official documentation for Varilrix does not list an egg allergy as a contraindication or precaution for its use. The vaccine's ingredients do not contain egg protein.
Q: Is Varilrix a common part of immunization schedules in other countries?
Varicella vaccination is recommended as part of the routine childhood immunization schedule in many countries worldwide. However, the specific schedule and use of monovalent versus combination vaccines can vary by national health authority.
Q: Is it normal to have a small rash after the Varilrix dose?
Yes, a rash is an officially documented side effect, classified as Common. This rash may be maculopapular (flat, red spots) or vesicular (small blisters), and may occur at the injection site or be generalized.
Q: How quickly do any general side effects from Varilrix typically appear?
The onset time varies by the specific side effect. Local reactions at the injection site, like redness and soreness, typically appear within the first 1 to 2 days. Other documented effects, such as a varicella-like rash or fever, may have a later onset, often one to three weeks following the dose.
Q: Are there specific studies about Varilrix in people with certain chronic conditions?
Regulatory documents discuss the use of the vaccine in specific patient groups who may be at high risk for severe disease, such as those with certain chronic conditions like chronic renal failure. In these cases, the professional guidance requires an evaluation to determine if the benefits of vaccination outweigh the potential risks based on specific clinical criteria.
Q: What does the patient information leaflet say about alcohol consumption around the time of the dose?
Official patient documents, such as the Patient Information Leaflet and the Summary of Product Characteristics, do not include any specific information or warnings regarding the consumption of alcohol around the time of receiving the vaccine dose.
Q: Is there a maximum age limit for receiving Varilrix?
Official approval extends to healthy adolescents and adults who are non-immune. Regulatory documents do not specify a fixed numerical upper age limit for the use of the vaccine in non-immune individuals.
Q: What is the general difference between Varilrix and the combination vaccine (if applicable)?
Varilrix is a single-agent (monovalent) vaccine that provides protection exclusively against the Varicella-zoster Virus (VZV). The combination vaccine (MMRV) provides simultaneous protection against VZV, measles, mumps, and rubella.
Q: Do health authorities track any potential long-term safety concerns related to Varilrix?
Yes, health authorities actively track and monitor potential safety concerns after the vaccine is licensed. This is achieved through established national and international post-marketing surveillance systems and adverse event reporting programs.
Q: Why is this vaccine described as important for healthcare workers?
Regulatory guidelines recommend vaccination for susceptible healthcare personnel because they are at risk of acquiring the virus and, potentially, transmitting it in healthcare settings. This is a measure to prevent infection of high-risk or immunocompromised patients.
Q: What research is available regarding the need for booster doses of Varilrix later in life?
The need for booster doses beyond the standard two-dose course has not yet been formally determined in the available regulatory research. Efficacy data currently extends up to nine years post-vaccination.
Q: What are the official guidelines regarding pregnancy and Varilrix?
The vaccine is formally contraindicated in pregnant women. Official guidelines recommend that pregnancy should be avoided for one month following the final dose. Specific schedules are in place for non-immune women who are postpartum.
Q: What is the clinical experience regarding fever after receiving Varilrix?
Fever (Pyrexia) is documented as a very common side effect. In clinical trials, a fever of 100.0 F (37.8 C) or higher was observed in approximately 10% of participants after either the first or second dose.
Q: Do studies suggest that previous vaccination with a different brand impacts the effectiveness of Varilrix?
Research has examined the safety profile when different brands of varicella vaccine (with different virus strains) are interchanged for the primary and second doses. These studies indicated that no new safety signals associated with interchanging the strains were observed in the studied population.
Q: What are the typical conditions or groups that are checked for eligibility before receiving Varilrix?
Official guidelines emphasize screening for several factors, including a history of hypersensitivity to the ingredients, immunosuppressed status, a recent history of receiving blood products or immune globulins, the presence of an acute severe febrile illness, and pregnancy status.
Q: What is the official guidance on exposure to others after receiving Varilrix?
Regulatory documents advise that the vaccinated person should avoid close contact with high-risk individuals who are susceptible to varicella, due to the theoretical possibility of transmitting the vaccine virus, as described in regulatory documents.
Q: Are there any specific lifestyle factors mentioned in official documents that could interfere with Varilrix?
Official documentation details specific drug and medical conditions that may interfere with the vaccine (such as high-dose steroids, recent immune globulins, or salicylates). No common, non-medical, daily lifestyle factors are listed as causing interference with the vaccine.
Q: What general expectations should patients have about how they feel in the week after receiving Varilrix?
In the first few days after the dose, common expectations often include local reactions such as pain, redness, and swelling at the injection site. Other documented effects like rash and fever typically appear later, often one to three weeks following the dose.
Q: Is it common to feel tiredness after receiving Varilrix?
The specific symptom of tiredness is not listed in the official classifications of very common, common, or uncommon side effects. However, fatigue (or asthenia), a related feeling, has been reported in post-marketing surveillance on a small number of occasions.
